People Are Sharing The Habits That Completely Destroyed Their Quality Of Life, And It's A Cautionary Tale
1."Taking on student loans."
—u/Beautiful-Signal7249
2."Worked 12-hour days for a job that wasn't worth it."
—u/sylphdreamer
3."Neglect my body for years. Almost no movement. Rather poor hygiene. Horrible food. And little to no sleep."
—u/Sad_Fee_4104
4."Succumbed to my food addiction...again. After two years of extreme dieting and exercise, I lost a significant amount of weight and achieved the best shape of my life, feeling very good about myself. Once I got down to an ideal weight, I didn't know what to do with myself anymore. I didn't know how to maintain it. I started eating horribly again and am now, just over a year later, at the heaviest point in my entire life. I binge eat to the extreme, and I'm pretty powerless to stop it. It affects pretty much every aspect of my life to some degree, and it's a very depressing feeling."
—u/NocturnaPhelps
5."Bulimia for 15 years since I was a teen. All because my mom signed me up for Weight Watchers as a kid, since I was a little chubby. Never felt thin enough. Ruined my teeth and digestive health. 10/10 do not recommend."
—u/ghostbustrnutclustr
6."Trying to impress people who don't GAF about you."
—u/Brave_Calendar_941
7."Decided to give working in a warehouse a shot. Quality of life went from 90% to below 50%."
—u/F3Grunge
8."Isolated myself for years. I'm not sure it could really have been otherwise with the issues I had, but it annihilated my social circle."
—u/NuclearSoil
9."Living with a boyfriend who rages."
—u/Equivalent_Hair_149
10."Vaped. Been nine months without it, and still cough and get winded easily. Used to sing as well and I can't hit notes for shit these days."
—u/Ok-East-8412
11."I was jumping on our kids' trampoline and I hurt my back, and I've suffered sciatica pain all these years since. My life would be so much better if I had not thought jumping on a trampoline would be good exercise."
—u/AvailableBreeze_3750
12."Spent years to impress the girl I like, I should have given that attention to my own self instead, improving my life."
—u/OkAccess6128
13."Holding out for a management position instead of moving on. He won't retire. The man is mid-70s."
—u/Funkyp0tat0chip
14."Trying to please people."
—u/OrchidCrushxoxo_
15."Not wearing earplugs at concerts."
—u/organicbooger
16."Moved to a new province (state) thinking I needed a fresh start, but in reality I was just running from my problems!"
—u/Smooth_Raspberry_007
17."Running too much in bad shoes. Now I have arthritis in my foot and I can't run anymore."
—u/justablueballoon
18."GET INTO DEBT!!!"
—u/ImpactSmooth299
19."Overeating."
—u/Different_Cat7932
20."Caring for others who do not give a damn about me in return. Wasted far too many sleepless nights on people who wouldn't give a flying monkey if I was in a situation like theirs."
—u/Party_Phrase2445
21."The wrong partner will wreck your life. I've been there, done that."
—u/Top-Car-808
22."I went rock climbing one day without a helmet on. The first time I didn't have it on was on the day it was needed. A Severe TBI is an injury I wish upon no man, woman, or child."
—u/Impressive-Dog-408
23."Smoked."
—u/Verlin_Wayne
24."Going to prison at 19 for selling weed. In the end, it worked out. I've since graduated from college and have a nice engineering job and a great life. It was a rough patch in my life for sure. Freezing, stuck in a prison cell in Joliet for 77 days, I went weeks without showers or seeing sunlight. Then, I was shipped off to boot camp for 4.5 months to be further denigrated. In the end, it caused me to grow up and prioritize what I want in life. Worked and paid my way through a 2-year community college, followed by a MIS degree at a 4-year University. Life hasn't been perfect, but I always have perspective on a 'bad day' in that I've had it much worse."
—u/leprechanmonkie
25."Putting effort into people who didn't do the same for me. Then getting anxiety over it."
—u/MeltyFrog
26."Stayed in my college major even after I knew it wasn't for me. I wasted a lot of time that I can never get back."
—u/SororitySue
27."Skipped the mammograms cause I had an 'it'll never happen to me' attitude when I was younger. Now I'm lying on a bed at a breast center waiting to get five biopsies for suspicious spots."
—u/Snowfall1201
28."Being understanding when someone treats/talks/screams at you like shit. Don't stand for it."
—u/Hangytangy
29."Ever touching nicotine."
—u/titsmuhgeee
30."Drinking wine every night."
—u/OpheliaJuliette
31."I left Walmart after 15 years to be a store manager at Starbucks —worst mistake of my life. I remember nights when I was there, ten after a closer called off, to have an opener call out, and knowing I'd have to wake up in four hours and work another shift, hoping the same thing wouldn't happen again. It was just awful, and the stories I'd hear from interviewing people made me realize how bad fast food was. People from other companies wanted to work at Starbucks cause those places were even worse."
—u/bendystrawboy
32."Social media. It has seriously messed with my attention span. And I can't even remember how to enjoy free time without checking it every five minutes."
—u/NeonPinkBag
33."Married young, at 18, now 61 divorced, wish I had planned my life better for my future first before I got married, I just didn't want to be alone."
—u/Ok-Dependent4293
34.And finally, "Dwelling on the past."
—u/Ball2daW-all
The National Eating Disorders Association helpline is 1-800-931-2237; for 24/7 crisis support, text 'NEDA' to 741741.
The National Alliance on Mental Illness helpline is 1-800-950-6264 (NAMI) and provides information and referral services; GoodTherapy.org is an association of mental health professionals from more than 25 countries who support efforts to reduce harm in therapy.
Is there a bad habit that you feel has derailed your entire life? Comment below on what you are doing to change it!
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
40 minutes ago
- Yahoo
Basilea receives USD 39 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, July 08, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services, committed the next USD 39 million to Basilea to continue to advance the development of Basilea's novel antifungals fosmanogepix and BAL2062. This additional funding is based on the successful completion of a milestone within the 'Other Transaction Agreement' (OTA, agreement number 75A50124C00033) that was awarded on September 30, 2024, and which allows for potential funding of up to approximately USD 268 million in total to develop antifungal and antibacterial assets. David Veitch, Chief Executive Officer of Basilea, said: 'We are very pleased to receive the continued funding under the OTA with BARDA to support the development of our antifungal drug candidates fosmanogepix and BAL2062. Both compounds offer a novel mechanism of action and represent new therapeutic options for patients with aspergillosis, candidiasis or other life-threatening fungal infections. These infections primarily affect patients with weakened immune systems, such as cancer or transplant patients. Infections with difficult-to-treat rare molds or with resistance to current therapies are increasing. Hence, there continues to be a high medical need for new innovative antifungals.' He added: 'This second tranche of funding within the BARDA OTA will support the ongoing phase 3 study with fosmanogepix in yeast infections and the second phase 3 study, in mold infections, which is expected to start soon. It also provides funding for the preparation for the start of the phase 2 study for our antifungal BAL2062.' The USD 39 million is in addition to the initial USD 29 million BARDA committed at the signing of the OTA in September 2024. BARDA's financial contribution is about 60% of the total costs of the supported projects over the term of the OTA, which could provide a total potential non-dilutive funding of up to approximately USD 268 million, over up to 12 years, if all additional options to extend the contract are exercised by BARDA, upon successful completion of pre-defined milestones, including clinical and regulatory activities. About fosmanogepix Fosmanogepix is a clinical-stage broad-spectrum antifungal. It has a novel mechanism of action and its active moiety has shown activity against common species of Candida and Aspergillus, including multi-drug-resistant strains, such as Candida auris and Candida glabrata, as well as rare difficult-to-treat molds including Fusarium spp., Scedosporium spp., and some fungi from the Mucorales order.1 Fosmanogepix intravenous and oral formulations have been evaluated in clinical phase 2 studies for the treatment of patients with Candidemia, including Candida auris infections, and invasive mold infections.1 A phase 3 study evaluating fosmanogepix in the treatment of adult patients with candidemia and/or invasive candidiasis is ongoing and the initiation of a second phase 3 study, in the treatment of adult patients with invasive mold infections, is expected soon.2 Fosmanogepix has received Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration for a number of indications, and is designated as a Qualified Infectious Disease Product (QIDP). About BAL2062 BAL2062 is a first-in-class antifungal, derived from a natural product, and has demonstrated fungicidal activity against clinically important molds such as Aspergillus spp., including azole-resistant strains.3 Safety and tolerability have been demonstrated in a previously completed phase 1 study with single and multiple ascending intravenous (i.v.) doses.4 The drug candidate has Qualified Infectious Disease Product (QIDP), Orphan Drug and Fast Track designation from the US Food and Drug Administration (FDA) for invasive aspergillosis. About invasive mold infections Invasive aspergillosis and invasive infections with rare molds (e.g., Fusarium spp., Scedosporium spp., and Mucorales fungi) are life-threatening infections that predominantly affect immunocompromised patients, including patients with hematologic malignancies (blood cancer), transplant patients, or patients with other immunodeficiency disorders. These infections are associated with high morbidity and mortality.5, 6 About invasive candidiasis Invasive candidiasis, including deep-seated tissue candidiasis and candidemia, is an increasingly important nosocomial infection, especially in patients hospitalized in intensive care units. Candida species are ranked as the fourth main cause of bloodstream infections in hospitals in the US.7 The prognosis of invasive candidiasis remains difficult, with a reported mortality rate for invasive candidiasis as high as 40%, even when patients receive antifungal therapy.8 About Basilea Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit Disclaimer This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd, Allschwil and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd, Allschwil to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd, Allschwil is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. This project has been funded in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under OT number: 75A50124C00033. The contract and federal funding are not an endorsement of the study results, product, or company. For further information, please contact: Peer Nils Schröder, PhD Head of Corporate Communications & Investor RelationsBasilea Pharmaceutica International Ltd, Allschwil Hegenheimermattweg 167b4123 AllschwilSwitzerland Phone +41 61 606 1102 E-mail media_relations@ This ad hoc announcement can be downloaded from References K. J. Shaw, A. S. Ibrahim. Fosmanogepix: A Review of the First-in-Class Broad Spectrum Agent for the Treatment of Invasive Fungal Infections. Journal of Fungi (Basel) 2020 (6), 239 FAST study (candidemia/invasive candidiasis): identifier NCT05421858; FORWARD study (invasive mold infections): identifier NCT06925321 K. J. Shaw. GR-2397: Review of the Novel Siderophore-like Antifungal Agent for the Treatment of Invasive Aspergillosis. Journal of Fungi (Basel) 2022 (8), 909 identifier NCT02956499: M. P. Mammen, D. Armas, F. H. Hughes et al. First-in-Human Phase 1 Study To Assess Safety, Tolerability, and Pharmacokinetics of a Novel Antifungal Drug, VL-2397, in Healthy Adults. Antimicrobial Agents and Chemotherapy 2019 (63), e00969-19 J. Cadena, G. R. Thompson 3rd, T. F. Patterson. Aspergillosis: Epidemiology, Diagnosis, and Treatment. Infectious Disease Clinics of North America 2021 (35), 415-434 M. Slavin, S. van Hal, T. C. Sorrell et al. Invasive infections due to filamentous fungi other than Aspergillus: epidemiology and determinants of mortality. Clinical Microbiology and Infection 2015 (21), 490.e1-490.e10 Candidemia (Blood Infection) and Other Candida Infections. 2019 Factsheet by the American Thoracic Society: (Accessed: July 07, 2025) B. J. Kullberg, M. C. Arendrup. Invasive Candidiasis. The New England Journal of Medicine 2015 (373), 1445-1456 Attachment Press release (PDF)
Yahoo
an hour ago
- Yahoo
Survey Shows Why People Skip Workouts and How to Fix It
Most of us are no stranger to skipping a workout class. Maybe we were a little too cozy in bed, riding out a hangover, or recovering from a night of tossing and turning. It happens. But turns out, we're creatures of habit in more ways than one. Not only do most people skip workouts for the same reasons, they tend to skip on the same days, too, according to new data from ClassPass, the monthly subscription service that lets members book everything from yoga to HIIT to open gym time. ClassPass analyzed three years of booking data to see when and why people actually bail on workouts. As it turns out, we're a lot more predictable than we think. The biggest spike in missed classes? July 5th, Daylight Savings Sunday, the day after Election Day, and January 1. "One of the more surprising patterns we uncovered is how late cancellations spike around specific calendar moments—not just early mornings or weekends," said Jeff Bladt, who leads marketplace strategy at ClassPass. "Year after year, certain dates reliably derail fitness routines."Out of all the skipped dates in the calendar year, January 1 stands out as the most unexpected, Bladt says. While it's the day most associated with fresh starts, it also seems to be the day when the most people ghost their goals just as the new year begins. "You'd think New Year's Day would be the biggest fitness boom, but it's actually the flakiest day in terms of cancellations," he says. "Across the U.S., more people ghost their workouts on January 1 than any other day." Out of all the days of the week, the data also revealed that Sunday mornings are the flakiest time slot overall, and early bird classes (think 5 to 6 a.m.) top the list of most likely to be ghosted. "Both Sunday mornings and early weekday mornings reveal an intention gap between someone's 'planning self' and their 'present self,'" Bladt says. "These time slots usually reflect strong intentions—to start the week fresh, to build a habit, to squeeze in fitness before the day gets busy. But when the alarm goes off, the snooze button often wins."Bladt emphasizes that it's not just one type of workout class taking the hit; everything from HIIT and spin to yoga and strength training sees a drop-off. "It's more that life happens, people want to sleep in, they prioritize social plans, and they miss those early classes," he says. Reig McConnell, CPT, CNC, and U.S. Army veteran, has heard just about every excuse for skipping a workout. But he has a few tricks for keeping his clients motivated, starting with helping them stay focused on their purpose. "To help keep my clients from bailing on their workouts for the long term, I use the analogy of building a house," he says. "Just like a house, your body is built brick by brick. At the end of this month or year, they're going to have to live in what we've built. Reminding them that every workout is a step in the right direction helps keep them motivated throughout the process as they work toward their final goal." Survey Shows Why People Skip Workouts and How to Fix It first appeared on Men's Journal on Jul 7, 2025
Yahoo
2 hours ago
- Yahoo
Exclusive-WeightWatchers names new medical chief, plans to offer menopause therapy and support
By Amina Niasse NEW YORK (Reuters) -WeightWatchers will announce on Tuesday Dr. Kim Boyd as its chief medical officer, and plans for a new program to help women manage the transition into menopause and beyond, part of its growth strategy in emerging from bankruptcy. Boyd, a Stanford University graduate who has worked with several consumer health startups, said in an interview that WeightWatchers is building upon its decades-long work providing weight management tools to also address the specific needs of people using obesity treatments. That includes Novo Nordisk's Wegovy and Eli Lilly's Zepbound. The company says its model promoting balanced eating and exercise helps subscribers reduce gastrointestinal side effects from the medicines and lose more weight on Wegovy. 'We have the foundation, and we will continue to evolve our programming to show up in a way that matches best with the addition of medications,' Boyd said. WeightWatchers CEO Tara Comonte said such support for members using weight-loss drugs should appeal to health insurers and employers who pay for health benefits as they seek more sustainable management of the costly medications. "It's a different business model and these partnerships and relationships take a much longer period of time than dialing up some direct to consumer marketing or promotional models," Comonte said. The program for perimenopause, menopause and post-menopause will include access to prescription treatments such as hormone replacement therapy, as well as behavioral and nutritional support for members, a significant proportion of whom are women ages 40 to 60 years old, WeightWatchers said. More details will become available later this year, the company, also known as WW International, said. 'It is a very natural overlap. In the perimenopausal and menopausal phase, up to 70% of women experience weight gain,' Boyd said. CHANGING WEIGHT LOSS MARKET Boyd previously served as national medical director at One Medical, a clinical business now owned by and later was chief medical officer at weight-management company Calibrate. Her appointment comes nearly a year after previous Chief Medical Officer Dr. Amy Meister stepped down. In the interim, WeightWatchers emerged from Chapter 11 bankruptcy, after struggling to compete with other online weight-management platforms selling cheaper, compounded versions of obesity treatments, including telehealth companies like Hims & Hers Health. The market for weight-management companies is changing since the U.S. Food and Drug Administration ordered an end to sales of compounded versions of Wegovy in late May. WeightWatchers last month announced a partnership with Novo Nordisk to sell Wegovy through the drugmaker's NovoCare pharmacy. Hims & Hers continues to offer smaller doses of compounded Wegovy than what is available from Novo, arguing they are providing a personalized medication that is not subject to the FDA ban. Industry analysts, however, have questioned whether that strategy will leave Hims vulnerable to legal challenges. Hims has said it also plans to expand into testosterone and menopause treatments as part of its growth strategy in the coming years. WeightWatchers has stopped selling compounded weight-loss drugs, and its partnership with Novo may prove more attractive to employer-sponsored health plans in the long run, Boyd said. "At the foundation of this is prescribing FDA-approved medications," Comonte said. 'We only prescribe branded drugs." A month's supply of Wegovy is listed at over $1,000 per month, but many people pay less through insurance. Cash-pay patients can access the treatment for $499 through NovoCare. 'For employers, some of them are finding value in these vendors like WeightWatchers... that give the members the lifestyle tools,' said Chantell Reagan, a senior director at advisory firm Willis Towers Watson. These strategies may help an employee sustain weight loss if they stop using a drug, she said. 'We are looking very closely at our employers that are using these programs and assessing the effectiveness.' Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
